All In Biotech

Drug Trial Radar · NCT07552012

A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIU

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of FXS5626 Tablets in Patients With Active Non-infectious Uveitis

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jan 29, 2026

Primary completion

Feb 28, 2027

Study completion Dec 31, 2027

Sponsor

Sponsor type
Industry
First posted
Apr 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to find out the efficacy and safety of oral FXS5626 in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).

Conditions

  • Active Non-anterior, Non-infectious Uveitis

Interventions

  • FXS5626 tabletDrug

    Administered twice per day for 24 weeks.

  • FXS5626 tabletOther

    Administered twice per day for 24 weeks.

  • PlaceboOther

    Administered twice per day for 24 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The percentage of patients meeting treatment failure criteria from week 6 to week 24.Time frame: 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • EC of the First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.